Azithromycin

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Community Acquired Pneumonia (CAP)

Conditions

Community Acquired Pneumonia (CAP)

Trial Timeline

Feb 1, 2009 → Mar 1, 2010

NCT ID

NCT00809328

About Azithromycin

Azithromycin is a phase 3 stage product being developed by Pfizer for Community Acquired Pneumonia (CAP). The current trial status is completed. This product is registered under clinical trial identifier NCT00809328. Target conditions include Community Acquired Pneumonia (CAP).

What happened to similar drugs?

2 of 12 similar drugs in Community Acquired Pneumonia (CAP) were approved

Approved (2) Terminated (2) Active (8)

✅IV azithromycin + ceftriaxone + oral azithromycin + IV levofloxacin + oral levofloxacinPfizerApproved

✅TelithromycinSanofiApproved

🔄Ceftaroline + CeftriaxonePfizerPhase 3

🔄Azithromycin microspheres 2.0 single dosePfizerPhase 3

🔄tigecyclinePfizerPhase 3

🔄Azithromycin SRPfizerPhase 3

❌Tigecycline + Tigecycline + cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside + CAP: Ceftriaxone, plus if applicable oral clarithromycinPfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (15)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00002089	Pre-clinical	Completed	—	—	Mycobacterium Avium-Intracellulare Infection
NCT00002309	Pre-clinical	Completed	—	—	Mycobacterium Avium-Intracellulare Infection
NCT00002344	Phase 1	Completed	—	—	Bacterial Infections
NCT00002082	Pre-clinical	Completed	—	—	Cryptosporidiosis
NCT00002139	Phase 1	Completed	—	—	Bacterial Infections
NCT00002328	Pre-clinical	Completed	—	—	Cryptosporidiosis
NCT00002085	Pre-clinical	Completed	—	—	Mycobacterium Avium-Intracellulare Infection
NCT00002090	Pre-clinical	Completed	—	—	Mycobacterium Avium-Intracellulare Infection
NCT01919996	Phase 2	Terminated	Dec 1, 2013	Nov 1, 2015	Pharyngitis
NCT00871494	Phase 3	Completed	May 1, 2009	Nov 1, 2010	Pelvic Inflammatory Disease
NCT00809328	Phase 3	Completed	Feb 1, 2009	Mar 1, 2010	Community Acquired Pneumonia (CAP)
NCT00939185	Pre-clinical	Completed	Apr 1, 2007	Jan 1, 2009	Respiratory Tract Infections
NCT00229944	Phase 3	Completed	Dec 1, 2002	May 1, 2004	Cholera
NCT01227395	Pre-clinical	Completed	Jul 1, 2002	Mar 1, 2012	HIV Infection
NCT00599079	Approved	Completed	Feb 1, 1993	May 18, 2017	Mycobacterium Avium Complex Lung Disease

Competing Products

17 competing products in Community Acquired Pneumonia (CAP)

See all competitors

Product	Company	Stage	Hype Score
ONO-5046Na + ONO-5046Na	Ono Pharmaceutical	Phase 2	35
Ticagrelor + Placebo	AstraZeneca	Phase 2	27
Ceftaroline + Ceftriaxone	Pfizer	Phase 3	40
Azithromycin microspheres 2.0 single dose	Pfizer	Phase 3	40
tigecycline	Pfizer	Phase 3	40
IV azithromycin + ceftriaxone + oral azithromycin + IV levofloxacin + oral levofloxacin	Pfizer	Approved	43
Azithromycin SR	Pfizer	Phase 3	40
Tigecycline + Tigecycline + cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside + CAP: Ceftriaxone, plus if applicable oral clarithromycin	Pfizer	Phase 3	32
Azithromycin SR + Amoxiclav	Pfizer	Pre-clinical	18
Tigecycline + Tigecycline + cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside + CAP: Ceftriaxone, plus if applicable oral clarithromycin	Pfizer	Phase 3	32
tigecycline	Pfizer	Phase 3	40
Zinforo (ceftaroline fosamil)	Pfizer	Pre-clinical	26
Tigecycline + Levofloxacin	Pfizer	Phase 3	40
Telithromycin	Sanofi	Approved	43
Omadacycline + Moxifloxacin	Zai Lab	Phase 3	41
ceftobiprole medocaril + IV standard-of-care cephalosporin	Basilea Pharmaceutica	Phase 3	34
EDP-420 / Duration of Treatment - 3 days + Telithromycin / Duration of Treatment - 7 days	Enanta Pharmaceuticals	Phase 2	21